Stability indicating RP-UPLC method for simultaneous estimation of atazanavir and cobicistat in bulk and tablet dosage forms

The present study was aimed to develop a novel, simple, rapid accurate and precise, stability-indicating reversed-phase Ultra-performance liquid chromatography method for the simultaneous estimation of Atazanavir and Cobicistat in bulk and tablet dosage forms. The chromatographic elution was achieved in isocratic mode using the combination of Atazanavir and Cobicistat in the ratio of 0.01N KH₂PO₄ and Acetonitrile (70: 30%v/v) using a HHS C18 column which has specification (100× 2.1mm, 1.8μ) and the flow rate of 0.3ml/min and wavelength detection at 237.0nm. The retention time obtained for Atazanavir and Cobicistat was 1.309 min, 1.607 min respectively. Atazanavir and Cobicistat their combination drug product were exposed to acidic, alkali, thermal, photolytic, and oxidative stress conditions. The current method was validated according to the ICH guidelines for accuracy, precision, linearity, specificity, and sensitivity.